Literature DB >> 16483945

[Induction chemotherapy and surgery of colorectal liver metastases].

René Adam1, Eric Vibert, Marcos Pitombo.   

Abstract

Surgery is the only curative treatment for patients with colorectal liver metastases with recent reports documenting 5-year survival results of 40-50%. In unresectable patients, the use of more effective regimens of chemotherapy has contributed to improve the results of survival at short term and new onco-surgical strategies have emerged. By allowing resection of previously unresectable liver metastases, these onco-surgical strategies now offer 15-20% of patients a real potential of long-term remission (5-year survival 30-40%). Chemotherapy is also used in the adjuvant setting, to prevent post-operative recurrence. In resectable metastases, it may also be used as neo-adjuvant treatment to control tumor progression before surgery and to select the patients likely to really benefit from liver resection. The objective of this article is to describe this multidisciplinary approach of liver metastases and to report the results of these new strategies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16483945

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  3 in total

Review 1.  Metastatic colorectal cancer-past, progress and future.

Authors:  Kathryn Field; Lara Lipton
Journal:  World J Gastroenterol       Date:  2007-07-28       Impact factor: 5.742

2.  Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontières meeting 2013.

Authors:  Alice Gillams; Nahum Goldberg; Muneeb Ahmed; Reto Bale; David Breen; Matthew Callstrom; Min Hua Chen; Byung Ihn Choi; Thierry de Baere; Damian Dupuy; Afshin Gangi; Debra Gervais; Thomas Helmberger; Ernst-Michael Jung; Fred Lee; Riccardo Lencioni; Ping Liang; Tito Livraghi; David Lu; Franca Meloni; Philippe Pereira; Fabio Piscaglia; Hyunchul Rhim; Riad Salem; Constantinos Sofocleous; Stephen B Solomon; Michael Soulen; Masatoshi Tanaka; Thomas Vogl; Brad Wood; Luigi Solbiati
Journal:  Eur Radiol       Date:  2015-05-22       Impact factor: 5.315

3.  Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study.

Authors:  Jean-Luc Raoul; Jean-Luc Van Laethem; Marc Peeters; Catherine Brezault; Fares Husseini; Laurent Cals; Johannes Nippgen; Anja-Helena Loos; Philippe Rougier
Journal:  BMC Cancer       Date:  2009-04-14       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.